THERAPY DOSSIER · th-33d6c671b3bd

Alginate scaffold seeded with CM-DiI-labelled bone marrow stromal cells

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26550170 ↗2015Reported benefit

Use an alginate scaffold-bone marrow stromal cell (BMSC) complex for the treatment of acute liver failure in rats.

RatOtherplaced onto the surface of the liver woundimmediately after 70% hepatectomy

Model: Acute liver failure induced by 70% hepatectomy

Rats receiving the alginate scaffold-bone marrow stromal cell complex had significantly higher survival and better liver function than those receiving scaffold alone, and the seeded cells secreted albumin and produced glycogen.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…